
Product Data Sheet

Product Name: Fenoldopam

Cat. No.: GC14759

Chemical Properties

Cas. No. 67227-56-9

Chemical Name 9-chloro-5-(4-hydroxyphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol

SMILES C1CNCC(C2=CC(=C(C(=C21)Cl)O)O)C3=CC=C(C=C3)OFormula $C_{16}H_{16}ClNO_3$ M.Wt 305.76Solubility $\geq 15.29\text{mg/mL}$ in DMSO Storage Store at -20°C General tips For obtaining a higher solubility, please warm the tube at 37°C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution: ship with blue ice. All other available size: ship with RT, or blue ice upon request.

Structure **Background**

Fenoldopam (SKF 82526) is a drug and synthetic benzazepine derivative which acts as a selective D1 receptor partial agonist. Target: D1 Receptor. Fenoldopam is a selective dopamine-1 (DA1) agonist with natriuretic/diuretic properties. Fenoldopam stimulated cAMP accumulation in LLC-PK1 cells in a dose-dependent manner, an effect which could be blocked by the DA1-selective antagonist Sch 23390. Although fenoldopam was more potent than DA (EC_{50} 55.5 \pm 7.75 nM vs. 1.65 \pm 0.64 μM) in stimulating cAMP accumulation in LLC-PK1 cells, the maximum stimulation obtained by fenoldopam was only 37% of the maximum stimulation obtained by DA (E_{max} 13.0 \pm 2.95 pmol/mg of protein vs. 35.6 \pm 10.19 pmol/mg of protein) [1]. Fenoldopam is a selective dopamine-1 (DA1) receptor agonist. Most of the DA1 receptor agonist activity of fenoldopam resides in the R-enantiomer, which also shows weaker α_2 -adrenoceptor antagonist activity. Fenoldopam produces vasodilation in vascular beds that are rich in vascular DA1 receptors [2].

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

References:

- [1]. Grenader, A. and D.P. Healy, Fenoldopam is a partial agonist at dopamine-1 (DA1) receptors in LLC-PK1 cells. J Pharmacol Exp Ther, 1991. 258(1): p. 193-8.
- [2]. Nichols, A.J., R.R. Ruffolo, Jr., and D.P. Brooks, The pharmacology of fenoldopam. Am J Hypertens, 1990. 3(6 Pt 2): p. 116S-119S.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA